Dominique Baeten

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis

Dominique Baeten, Joachim Sieper, Jürgen Braun et al. · New England Journal of Medicine · 2015 · 1K citations · Full text

Life Sciences, Immunology, Pharmacotherapy +13

Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial

Dominique Baeten, Xenofon Baraliakos, Jürgen Braun et al. · The Lancet · 2013 · 590 citations

Medicine, Clinical Sciences, Immunology +14

Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis

Jasper J. Haringman, Daniëlle M. Gerlag, Aeilko H. Zwinderman et al. · Annals of the Rheumatic Diseases · 2004 · 464 citations · Full text

Medicine, Immunology, Pathology +17

Systematic validation of specific phenotypic markers for in vitro polarized human macrophages

Carmen A. Ambarus, Sarah Krausz, Marco van Eijk et al. · Journal of Immunological Methods · 2011 · 414 citations

Life Sciences, Cell Biology, Immunology +12

Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study

Dominique Baeten, Mikkel Østergaard, James Cheng‐Chung Wei et al. · Annals of the Rheumatic Diseases · 2018 · 374 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10